, Johansen, L., Schmid, R., Ugelstand,
J., Ellingsen, T. and Berge, A. Agents Actions
Suppl., 9, 207-212, (1982).
21. Tenoso, H.J., Smith, D.B., Covalent Bonding of
Antibodies to Polystyrene Latex
, Johansen, L., Schmid, R., Ugelstand,
J., Ellingsen, T. and Berge, A. Agents Actions
Suppl., 9, 207-212, (1982).
21. Tenoso, H.J., Smith, D.B., Covalent Bonding of
Antibodies to Polystyrene Latex
, Johansen, L., Schmid, R., Ugelstand,
J., Ellingsen, T. and Berge, A. Agents Actions
Suppl., 9, 207-212, (1982).
21. Tenoso, H.J., Smith, D.B., Covalent Bonding of
Antibodies to Polystyrene Latex
, Johansen, L., Schmid, R., Ugelstand,
J., Ellingsen, T. and Berge, A. Agents Actions
Suppl., 9, 207-212, (1982).
21. Tenoso, H.J., Smith, D.B., Covalent Bonding of
Antibodies to Polystyrene Latex
K., Johansen, L., Schmid, R., Ugelstand, J., Ellingsen, T. and Berge, A. Agents Actions Suppl., 9, 207-
212, (1982).
21. Tenoso, H.J., Smith, D.B., Covalent Bonding of Antibodies to Polystyrene Latex
) channels in
the hippocampus is regulated by developmental seizures. Neurobiol Dis 19(1-2),
200-207.
Chaplan, S. R., Guo, H. Q., Lee, D. H., Luo, L., Liu, C., Kuei, C., Velumian, A. A.,
Butler, M
) channels in
the hippocampus is regulated by developmental seizures. Neurobiol Dis 19(1-2),
200-207.
Chaplan, S. R., Guo, H. Q., Lee, D. H., Luo, L., Liu, C., Kuei, C., Velumian, A. A.,
Butler, M
P2482 207 AKT1 M NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
575 Protein Kinase Ba /Akt1 P1601 207 AKT1 P NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
577 phospho-PKB (pSer473) P4112 207 AKT1
P2482 207 AKT1 M NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
575 Protein Kinase Ba /Akt1 P1601 207 AKT1 P NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
577 phospho-PKB (pSer473) P4112 207 AKT1
P2482 207 AKT1 M NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
575 Protein Kinase Ba /Akt1 P1601 207 AKT1 P NP_001014431.1,NP_001014432.1 , NP_005154.2, y y y
577 phospho-PKB (pSer473) P4112 207 AKT1
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
P-Glycoprotein, BCRP, and MRP2 in Caco-2 Cells." Drug Metabolism and Disposition 43.2 (2015):
199-207.
Shalem, O. et al., Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells. Science 2014;
alternate-packaging needs, contact
any member of the Novagen Bulk Team:
USA and Canada
Tel: 1 800 207 0144
Email: bulk@novagen.com
Germany
Tel: 0800 69 31 000
Email: customer.service@
merckbiosciences.de
001101103.1 M y y y
574 Protein Kinase Bα /Akt1 P2482 207, 11651, 24185 AKT1,Akt1 NP_005154.2,NP_033782.1,NP_150233.1 M y y y
575 Protein Kinase Bα /Akt1 P1601 207, 11651, 24185 AKT1,Akt1 NP_005154.2,NP_033782.1
001101103.1 M y y y
574 Protein Kinase Bα /Akt1 P2482 207, 11651, 24185 AKT1,Akt1 NP_005154.2,NP_033782.1,NP_150233.1 M y y y
575 Protein Kinase Bα /Akt1 P1601 207, 11651, 24185 AKT1,Akt1 NP_005154.2,NP_033782.1
Format Host Quantity Cat. No.
Recombinant Growth Factor
Insulin (Arg-Insulin) CULT 10 mg 01-207
Incelligent™ SG, recombinant human Pur 1 g 4502-01
Incelligent AF, recombinant human Pur 1 g
spectrometry-based proteomics.
Nature, 422, 198-207 (2003).
4. Dreisewerd, K., The desorption process in MALDI. Chem. Rev., 103,
395-425 (2003).
5. Karas, M., and Krüger, R., Ion formation in MALDI